Andrew Yee, MD, discusses lenalidomide plus ixazomib, dexamethasone, and daratumumab in newly diagnosed multiple myeloma.
Andrew Yee, MD
Advertisement
Articles by Andrew Yee, MD
Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.
Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.
Andrew Yee, MD, discusses the phase 3 CANDOR trial in relapsed/refractory multiple myeloma.
Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.
Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.
Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple MyelomaPublished: April 22nd 2020 | Updated:
Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple MyelomaPublished: May 4th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5